ES2196377T3 - Derivados de naftiridina. - Google Patents

Derivados de naftiridina.

Info

Publication number
ES2196377T3
ES2196377T3 ES97948803T ES97948803T ES2196377T3 ES 2196377 T3 ES2196377 T3 ES 2196377T3 ES 97948803 T ES97948803 T ES 97948803T ES 97948803 T ES97948803 T ES 97948803T ES 2196377 T3 ES2196377 T3 ES 2196377T3
Authority
ES
Spain
Prior art keywords
naftiridine
derivatives
compounds
invention refers
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97948803T
Other languages
English (en)
Inventor
Rene Hersperger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2196377T3 publication Critical patent/ES2196377T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

LA INVENCION SE REFIERE A NUEVAS 8 - ARIL - 1,7 NAFTIRIDINAS, EN FORMA LIBRE O DE SAL, QUE SON INHIBIDORES DE PDE IV Y SON, POR TANTO, UTILES COMO AGENTES FARMACEUTICOS, P.EJ. PARA TERAPIA DEL ASMA. LOS COMPUESTOS PREFERIDOS COMPRENDEN COMPUESTOS DE FORMULAS (I Y II), DONDE LOS GRUPOS R SON TAL Y COMO SE DEFINEN EN LA DESCRIPCION. LA INVENCION SE REFIERE ASIMISMO A COMPOSICIONES QUE COMPRENDEN DICHOS COMPUESTOS, A PROCEDIMIENTOS DE PREPARACION DE LOS MISMOS Y A NUEVOS INTERMEDIARIOS PARA SU UTILIZACION EN DICHOS PROCEDIMIENTOS.
ES97948803T 1996-10-28 1997-10-24 Derivados de naftiridina. Expired - Lifetime ES2196377T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9622386.2A GB9622386D0 (en) 1996-10-28 1996-10-28 Organic compounds

Publications (1)

Publication Number Publication Date
ES2196377T3 true ES2196377T3 (es) 2003-12-16

Family

ID=10802050

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97948803T Expired - Lifetime ES2196377T3 (es) 1996-10-28 1997-10-24 Derivados de naftiridina.

Country Status (32)

Country Link
US (1) US6136821A (es)
EP (1) EP0934320B1 (es)
JP (1) JP4451496B2 (es)
KR (1) KR100524329B1 (es)
CN (1) CN1103773C (es)
AR (1) AR009128A1 (es)
AT (1) ATE236155T1 (es)
AU (1) AU724471B2 (es)
BR (1) BR9713280B1 (es)
CA (1) CA2269946C (es)
CO (1) CO4910164A1 (es)
CZ (1) CZ146699A3 (es)
DE (1) DE69720493T2 (es)
DK (1) DK0934320T3 (es)
ES (1) ES2196377T3 (es)
GB (1) GB9622386D0 (es)
HK (1) HK1022305A1 (es)
HU (1) HUP9904204A3 (es)
ID (1) ID18623A (es)
IL (2) IL129502A0 (es)
MY (1) MY132642A (es)
NO (1) NO312677B1 (es)
NZ (1) NZ335363A (es)
PE (1) PE10899A1 (es)
PL (1) PL189280B1 (es)
PT (1) PT934320E (es)
SI (1) SI0934320T1 (es)
SK (1) SK283562B6 (es)
TR (1) TR199900920T2 (es)
TW (1) TW399052B (es)
WO (1) WO1998018796A1 (es)
ZA (1) ZA979593B (es)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002534505A (ja) 1999-01-15 2002-10-15 ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング 新規フェナントリジン−ｎ−オキシド
JP2003502278A (ja) * 1999-01-15 2003-01-21 ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング 新規のｎ−オキシド
CZ302882B6 (cs) 1999-08-21 2012-01-04 Nycomed Gmbh Farmaceutický prostredek
US6953774B2 (en) 2000-08-11 2005-10-11 Applied Research Systems Ars Holding N.V. Methods of inducing ovulation
CN1527830A (zh) 2001-01-31 2004-09-08 �Ʒ� 用作pde4同工酶的抑制剂的醚衍生物
OA12540A (en) 2001-01-31 2006-06-05 Pfizer Prod Inc Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes.
US7250518B2 (en) 2001-01-31 2007-07-31 Pfizer Inc. Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
KR20030072614A (ko) 2001-01-31 2003-09-15 화이자 프로덕츠 인크. Ｐｄｅ４ 이소자임 억제제로 유용한 티아졸릴-,옥사졸릴-, 피롤릴- 및 이미다졸릴-산 아미드 유도체
CA2447618A1 (en) * 2001-05-23 2002-11-28 Tanabe Seiyaku Co., Ltd. A composition for regenerative treatment of cartilage disease
MXPA04003516A (es) 2001-10-16 2004-07-23 Memory Pharm Corp Derivados de 4-(4-alcoxi-3-hidroxifenil)-2-pirrolidona como inhibidores de pde-4 para el tratamiento de sindromes neurologicos.
MY130622A (en) 2001-11-05 2007-07-31 Novartis Ag Naphthyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors
ES2293965T3 (es) 2001-12-14 2008-04-01 Laboratoires Serono Sa Metodo de inducir la ovulacion utilizando un modulador no polipeptidico de los niveles de camp.
NZ540138A (en) 2002-11-19 2008-07-31 Memory Pharm Corp Pyridine n-oxide compounds as phosphodiesterase 4 inhibitors
GB0229281D0 (en) * 2002-12-16 2003-01-22 Novartis Ag Organic compounds
CN1805929A (zh) * 2003-04-16 2006-07-19 记忆药物公司 磷酸二酯酶4抑制剂
AU2004232973A1 (en) * 2003-04-18 2004-11-04 Memory Pharmaceuticals Corporation Pyrazole derivatives as phosphodiesterase 4 inhibitors
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
MY141255A (en) 2003-12-11 2010-03-31 Memory Pharm Corp Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
US20090042951A1 (en) * 2004-02-20 2009-02-12 Robert Danziger Blood Pressure Reduction in Salt-Sensitive Hypertension
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
WO2006002284A1 (en) * 2004-06-22 2006-01-05 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
KR20070053245A (ko) * 2004-09-14 2007-05-23 노파르티스 아게 8-할로-'1,7 나프트피리딘-유도체와 유기 보론산 유도체의반응에 의한 6,8-치환된 '1,7 나프트피리딘 유도체의 제조방법, 및 상기 방법의 중간체
AU2005295753A1 (en) 2004-10-15 2006-04-27 Memory Pharmaceuticals Corporation Pyrazole derivatives as phosphodiesterase 4 inhibitors
JP2008517066A (ja) * 2004-10-20 2008-05-22 メモリー ファーマシューティカルス コーポレーション ホスホジエステラーゼ４阻害剤
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
JP2006241111A (ja) * 2005-03-04 2006-09-14 Univ Nihon 新規ベンゾフロキサン及びその合成法
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
EP1954697B1 (en) * 2005-10-21 2010-02-24 Glaxo Group Limited Peri condensed tricyclic compounds useful as antibacterial agents
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
AR058104A1 (es) 2005-10-21 2008-01-23 Novartis Ag Compuestos organicos
EP1942879A1 (en) 2005-10-31 2008-07-16 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
GB0526244D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
JP2009520779A (ja) 2005-12-22 2009-05-28 グラクソ グループ リミテッド 複素環化合物、その製造およびその抗菌剤としての使用
GB0601951D0 (en) * 2006-01-31 2006-03-15 Novartis Ag Organic compounds
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
PT2322525E (pt) 2006-04-21 2013-12-26 Novartis Ag Derivados de purina para utilização como agonistas do recetor de adenosina a2a
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
CA2651862A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
BRPI0716604A2 (pt) 2006-09-08 2013-04-09 Braincells Inc combinaÇÕes contendo um derivado de 4-acilaminopiridina
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
JP2010504933A (ja) 2006-09-29 2010-02-18 ノバルティス アーゲー Ｐｉ３ｋ脂質キナーゼ阻害剤としてのピラゾロピリミジン
EP2089393A1 (en) 2006-10-30 2009-08-19 Novartis AG Heterocyclic compounds as antiinflammatory agents
PL2104535T3 (pl) 2007-01-10 2011-05-31 Irm Llc Związki i kompozycje jako inhibitory proteazy aktywujące kanały
DE602008005140D1 (de) 2007-05-07 2011-04-07 Novartis Ag Organische verbindungen
EP2231280B1 (en) 2007-12-10 2016-08-10 Novartis AG Amiloride-like Pyrazine-carboxamides as ENaC blockers
PL2231642T3 (pl) 2008-01-11 2014-04-30 Novartis Ag Pirymidyny jako inhibitory kinazy
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
ES2535736T3 (es) 2008-06-10 2015-05-14 Novartis Ag Derivados de pirazina como bloqueadores de los canales de sodio epitelial
US20110281917A1 (en) 2009-01-29 2011-11-17 Darrin Stuart Substituted Benzimidazoles for the Treatment of Astrocytomas
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
AU2010283806A1 (en) 2009-08-12 2012-03-01 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
SG178454A1 (en) 2009-08-17 2012-03-29 Intellikine Inc Heterocyclic compounds and uses thereof
JP5775871B2 (ja) 2009-08-20 2015-09-09 ノバルティス アーゲー ヘテロ環式オキシム化合物
EP2490687A1 (en) 2009-10-22 2012-08-29 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
WO2012007539A1 (en) 2010-07-14 2012-01-19 Novartis Ag Ip receptor agonist heterocyclic compounds
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
WO2012107500A1 (en) 2011-02-10 2012-08-16 Novartis Ag [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
WO2012116217A1 (en) 2011-02-25 2012-08-30 Irm Llc Compounds and compositions as trk inhibitors
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
JP5957526B2 (ja) 2011-09-15 2016-07-27 ノバルティス アーゲー チロシンキナーゼとしての６−置換３−（キノリン−６−イルチオ）−［１，２，４］トリアゾロ［４，３−ａ］ピラジン
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
CN103946221B (zh) 2011-09-16 2016-08-03 诺华股份有限公司 用于治疗囊性纤维化的杂环化合物
EP2755652B1 (en) 2011-09-16 2021-06-02 Novartis AG N-substituted heterocyclyl carboxamides
WO2013078440A2 (en) 2011-11-23 2013-05-30 Intellikine, Llc Enhanced treatment regimens using mtor inhibitors
US20150119399A1 (en) 2012-01-10 2015-04-30 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
ES2565826T3 (es) 2012-01-13 2016-04-07 Novartis Ag Pirroles fusionados como agonistas del receptor IP para el tratamiento de hipertensión arterial pulmonar (PAH) y trastornos relacionados
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
CN110507654A (zh) 2012-04-03 2019-11-29 诺华有限公司 有酪氨酸激酶抑制剂的组合产品和其应用
JP5907005B2 (ja) * 2012-09-04 2016-04-20 エヌ・イーケムキャット株式会社 ビフェニル化合物の合成方法
JP5907006B2 (ja) * 2012-09-04 2016-04-20 エヌ・イーケムキャット株式会社 ビフェニル化合物の合成方法
WO2014125413A1 (en) 2013-02-13 2014-08-21 Novartis Ag Ip receptor agonist heterocyclic compounds
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
JP2016512835A (ja) 2013-03-15 2016-05-09 インテリカイン， エルエルシー キナーゼ阻害剤の組み合わせ及びそれらの使用
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
EP3134397A1 (en) 2014-04-24 2017-03-01 Novartis AG Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
WO2015162461A1 (en) 2014-04-24 2015-10-29 Novartis Ag Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
CA2945069A1 (en) 2014-04-24 2015-10-29 Novartis Ag Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
US9741941B2 (en) 2014-04-29 2017-08-22 Universal Display Corporation Organic electroluminescent materials and devices
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
US10195208B2 (en) 2014-07-31 2019-02-05 Novartis Ag Combination therapy
EP3980121A1 (en) 2019-06-10 2022-04-13 Novartis AG Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis
US20220306617A1 (en) 2019-08-28 2022-09-29 Novartis Ag Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54138572A (en) * 1978-04-17 1979-10-27 Kyowa Hakko Kogyo Co Ltd Novel isoquinoline derivative
JPS57203068A (en) * 1981-06-08 1982-12-13 Teikoku Hormone Mfg Co Ltd Novel 1-phenylisoquinoline derivative
FR2567520B1 (fr) * 1984-07-11 1987-01-02 Carpibem Nouvelles phenyl-naphthyridines, leur procede de preparation, medicaments les contenant, notamment anti-ulceres
JPS6230780A (ja) * 1985-04-17 1987-02-09 Ss Pharmaceut Co Ltd １，７−ナフチリジン誘導体及びこれを含有する薬剤
JPS6348277A (ja) * 1986-08-19 1988-02-29 Ss Pharmaceut Co Ltd ８−ピペラジニル−１，７−ナフチリジン誘導体
GB8800397D0 (en) * 1988-01-08 1988-02-10 Sandoz Ltd Improvements in/relating to organic compounds
US4956371A (en) * 1989-09-19 1990-09-11 Euroceltique, S.A. Substituted isoquinolines and methods of using same
US5466697A (en) * 1994-07-13 1995-11-14 Syntex (U.S.A.) Inc. 8-phenyl-1,6-naphthyridin-5-ones
WO1998035967A2 (en) * 1997-02-18 1998-08-20 Neurocrine Biosciences, Inc. Biazacyclic crf antagonists

Also Published As

Publication number Publication date
EP0934320A1 (en) 1999-08-11
NO312677B1 (no) 2002-06-17
AU6908498A (en) 1998-05-22
NZ335363A (en) 2000-11-24
DE69720493D1 (de) 2003-05-08
NO991903L (no) 1999-04-21
DE69720493T2 (de) 2003-12-24
SK55799A3 (en) 1999-10-08
HUP9904204A2 (hu) 2000-05-28
CZ146699A3 (cs) 1999-08-11
BR9713280B1 (pt) 2010-12-14
TW399052B (en) 2000-07-21
SK283562B6 (sk) 2003-09-11
DK0934320T3 (da) 2003-07-14
GB9622386D0 (en) 1997-01-08
KR20000052832A (ko) 2000-08-25
PT934320E (pt) 2003-07-31
US6136821A (en) 2000-10-24
BR9713280A (pt) 1999-11-03
ATE236155T1 (de) 2003-04-15
HUP9904204A3 (en) 2000-06-28
HK1022305A1 (en) 2000-08-04
NO991903D0 (no) 1999-04-21
SI0934320T1 (en) 2003-08-31
KR100524329B1 (ko) 2005-11-01
TR199900920T2 (xx) 1999-06-21
AR009128A1 (es) 2000-03-08
PL332738A1 (en) 1999-10-11
IL129502A0 (en) 2000-02-29
CO4910164A1 (es) 2000-04-24
CN1103773C (zh) 2003-03-26
PE10899A1 (es) 1999-03-03
JP4451496B2 (ja) 2010-04-14
MY132642A (en) 2007-10-31
PL189280B1 (pl) 2005-07-29
WO1998018796A1 (en) 1998-05-07
CA2269946A1 (en) 1998-05-07
ID18623A (id) 1998-04-30
CN1234800A (zh) 1999-11-10
ZA979593B (en) 1998-04-28
IL129502A (en) 2006-10-05
JP2001502717A (ja) 2001-02-27
EP0934320B1 (en) 2003-04-02
CA2269946C (en) 2007-01-23
AU724471B2 (en) 2000-09-21

Similar Documents

Publication Publication Date Title
ES2196377T3 (es) Derivados de naftiridina.
CO5271715A1 (es) 7-aza-indolin-2-onas sustituidas en 4 y su uso como inhibidores de proteiuna quinasa
ES2186015T3 (es) Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol.
AR023574A1 (es) Compuestos de azepinindol tetraciclico,composiciones farmaceuticas y el uso de dichos compuestos para preparar un medicamento, e intermediarios
PA8582801A1 (es) Nuevos derivados espirotricíclicos y su uso como inhibidores de la fosfodiesterasa
BR9907886A (pt) Composto, uso do mesmo, composição farmacêutica, e, processo de tratamento ou profilaxia de doenças inflamatórias, por exemplo asma ou copd.
AR028948A1 (es) Compuestos novedosos
ECSP045004A (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes
AR023727A1 (es) Compuestos empleados en el tratamiento de padecimientos inflamatorios
AR021844A1 (es) Derivados de propanolamina aril-sustituidos, procedimientos para su preparacion, medicamentos que contienen estos compuestos y su utilizacion
BR9907270A (pt) Composto, composição farmacêutica, uso de um composto, e, processos para tratamento ou profilaxia de doenças inflamatórias, por exemplo, asma ou copd, e para a preparação de um composto
SV1998000008A (es) Inhibisores de sulfamida-metaloproteasa. ref. ran 4070\114
ES2139959T3 (es) Derivados de estilbeno utiles como inhibidores de la ciclooxigenasa-2.
ES2058185T3 (es) Derivados de camptotecina y procedimiento para su preparacion.
BR9911482A (pt) Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto
ES2136037B1 (es) Inhibidores de sulfamida-metaloproteasa
ES2193391T3 (es) Antagonistas muscarinicos.
ECSP066383A (es) Derivados de 5-fenil-4-metil-tiazol-2-il-amina como inhibidores de enzimas de cinasa fosfatidilinositol 3 (pi3) para el tratamiento de enfermedades inflamatorias de las vías respiratorias
ECSP034914A (es) "azaindoles"
MX9308012A (es) Eteres fosfonooximetilicos de derivados de taxano, solubles en agua y composiciones farmaceuticas que los incluyen.
PA8432901A1 (es) Compuestos de piridilpirrol
PA8485601A1 (es) Azalidas de 13 miembros y su uso como agentes antibioticos.
AR021843A1 (es) Derivados de propanolamina sustituidos con heterociclos, procedimiento para su preparacion, y su utilizacion.
PA8487701A1 (es) Derivados de 3,3-biarilpiperidina y 2,2-biarilmorfolina
AR018162A1 (es) Pirroles substituidos, composicion farmaceutica y el uso de los mismos para la preparacion de dicha composicion farmaceutica